Enhanced adjuvanticity of interleukin-2 plasmid DNA administered in polyethylenimine complexesOH, Yu-Kyoung; PARK, Jeong-Sook; KANG, Min-Jeong et al.Vaccine. 2003, Vol 21, Num 21-22, pp 2837-2843, issn 0264-410X, 7 p.Article

The effect of Freund's adjuvants on blood-cerebrospinal fluid barrier permeabilityREIBER, H; SUCKLING, A. J; RUMSBY, M. G et al.Journal of the neurological sciences. 1984, Vol 63, Num 1, pp 55-61, issn 0022-510XArticle

Adjuvants and delivery systems in veterinary vaccinology: current state and future developmentsHEEGAARD, Peter M. H; DEDIEU, Laurence; JOHNSON, Nicholas et al.Archives of virology. 2011, Vol 156, Num 2, pp 183-202, issn 0304-8608, 20 p.Article

Vaccine with herbal adjuvant-A better cocktail to combat the infectionSAKURE, Sandhya; VIDYA DEVI NEGI; SHANKAR KUMAR MITRA et al.Vaccine. 2008, Vol 26, Num 27-28, pp 3387-3388, issn 0264-410X, 2 p.Article

VITAMIN A ADJUVANT WITH ARIZONA HINSHAWII BACTERINADLER HE; DAMASSA AJ.1972; APPL. MICROBIOL.; U.S.A.; DA. 1972; VOL. 24; NO 5; PP. 849-850; BIBL. 4 REF.Serial Issue

EMPLOI DE GEL D'ACRYLAMIDE COMME ADJUVANT DANS LA PREPARATION D'IMMUNSERUMSBEDNARIK T; CAJTHAMLOVA H; SOLAR V et al.1973; CESKOSL. EPIDEMIOL. MIKROBIOL. IMUNOL.; CESKOSL.; DA. 1973; VOL. 22; NO 3; PP. 141-145; H.T. 2; ABS. RUSSE ANGL.; BIBL. 5REF.Serial Issue

Disparate adjuvant properties among three formulations of alumCAIN, Derek W; SANDERS, Sergio E; CUNNINGHAM, Michael M et al.Vaccine. 2013, Vol 31, Num 4, pp 653-660, issn 0264-410X, 8 p.Article

Co-stimulatory agonists as immunological adjuvantsBARR, Tom A; CARLRING, Jennifer; HEATH, Andrew W et al.Vaccine. 2006, Vol 24, Num 17, pp 3399-3407, issn 0264-410X, 9 p.Article

European union regulatory developments for new vaccine adjuvants and delivery systemsSESARDIC, Dorothea; DOBBELAER, Roland.Vaccine. 2004, Vol 22, Num 19, pp 2452-2456, issn 0264-410X, 5 p.Conference Paper

Vaccine AdjuvantsREED, Steven G.Expert review of vaccines. 2013, Vol 12, Num 7, issn 1476-0584, [112 p.]Serial Issue

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases : Vaccines and AdjuvantsBAZ MORELLI, Adriana; BECHER, Dorit; KOERNIG, Sandra et al.Journal of medical microbiology. 2012, Vol 61, Num 7, pp 935-943, issn 0022-2615, 9 p.Conference Paper

The safety evaluation of adjuvants during vaccine development: The AS04 experienceGARCON, Nathalie; SEGAL, Lawrence; TAVARES, Fernanda et al.Vaccine. 2011, Vol 29, Num 27, pp 4453-4459, issn 0264-410X, 7 p.Article

VACCINS Les adjuvants en renfort ! = Vaccins and adjuvants for enhancing immunityLARGETEAU, Quitterie.Découverte (Paris. 1999). 2012, Num 383, pp 26-35, issn 1621-0085, 10 p.Article

Preformulation studies—The next advance in aluminum adjuvant-containing vaccinesHEM, Stanley L; HOGENESCH, Harm; MIDDAUGH, C. Russell et al.Vaccine. 2010, Vol 28, Num 31, pp 4868-4870, issn 0264-410X, 3 p.Article

ETUDE CHEZ LA SOURIS DU POUVOIR ADJUVANT D'UNE ENDOTOXINE BACTERIENNE AU COURS DE LA VACCINATION PAR AEROSOLS D'ANATOXINE TETANIQUE LYOPHILISEELECLERCQ P.1971; ; S.L.; DA. 1971; PP. (98P.); BIBL. 16P.1/2; (THESE DOCT. UNIV., SECT. PHARM.; UNIV. CLAUDE BERNARD LYONI)Thesis

Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on CancerCOHEN, Robert L.Current Topics in Microbiology and Immunology. 2012, Vol 355, pp 217-232, issn 0070-217X, 16 p.Article

Adjuvants in tuberculosis vaccine developmentMORENO-MENDIETA, Silvia A; ROCHA-ZAVALETA, Leticia; RODRIGUEZ-SANOJA, Romina et al.FEMS immunology and medical microbiology (Print). 2010, Vol 58, Num 1, pp 75-84, issn 0928-8244, 10 p.Conference Paper

Vaccine adjuvants revisitedAGUILAR, J. C; RODRIGUEZ, E. G.Vaccine. 2007, Vol 25, Num 19, pp 3752-3762, issn 0264-410X, 11 p.Article

Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid ATIBERIO, Lorrie; FLETCHER, Leah; ELDRIDGE, John H et al.Vaccine. 2004, Vol 22, Num 11-12, pp 1515-1523, issn 0264-410X, 9 p.Article

Mitogenic, immunoadjuvancy, and genetic studies on fatty acyl maltoseBISSONNETTE, E; BENREZZAK, O; MADARNAS, P et al.Cancer immunology and immunotherapy. 1988, Vol 27, Num 3, pp 272-277, issn 0340-7004Article

Nanotechnology for vaccine developmentTOTH, Istvan; SKWARCZYNSKI, Mariusz.Nanomedicine (London. Print). 2014, Vol 9, Num 17, issn 1743-5889, [112 p.]Serial Issue

TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccinesTUDOR, Daniela; DUBUQUOY, Catherine; GABORIAU, Valérie et al.Vaccine. 2005, Vol 23, Num 10, pp 1258-1264, issn 0264-410X, 7 p.Article

Adjuvants in perspectiveVOGEL, F. R.Developments in biological standardization. 1998, Num 92, pp 241-248, issn 0301-5149Conference Paper

Nanoparticle vaccinesLIANG ZHAO; SETH, Arjun; WIBOWO, Nani et al.Vaccine. 2014, Vol 32, Num 3, pp 327-337, issn 0264-410X, 11 p.Article

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effectCALABRO, Samuele; TRITTO, Elaine; PEZZOTTI, Annamaria et al.Vaccine. 2013, Vol 31, Num 33, pp 3363-3369, issn 0264-410X, 7 p.Article